准分子激光原位角膜磨镶术后10年分析  

Ten years outcomes after laser in situ keratomileusis for myopia

作　　者：王跃静[1] 徐新荣[1] 张玉娟[1] 吴静[1] 张传伟[1] 

机构地区：[1]江苏省中医院眼科,江苏南京210029

出　　处：《南京医科大学学报（自然科学版）》2010年第12期1760-1763,共4页Journal of Nanjing Medical University(Natural Sciences)

摘　　要：目的:评价准分子激光原位角膜磨镶术矫正近视术后10年的远期疗效和安全性。方法:对在本院接受准分子激光原位角膜磨镶术矫正近视术后10年的患者39例77眼进行裸眼视力、屈光度和最佳矫正视力及角膜厚度和Orbscan的检查。被随访眼按屈光度数分为2组:≤-6.0 D组和>6.0 D组,同时采用本院近期手术的近视眼患者的术前检查资料设为对照组。结果:术后10年组裸眼视力≥1.0的低、高度数组分别为63%,42%;<1.0分别为27%,58%;最佳矫正视力≥1.0的分别为98%,72%(P≤0.05)。与术前相比,术后10年Orbscan提供的前、后表面的Diff值及3 mm、5 mm的Irreg及角膜厚度均有统计学差异(P<0.01);术后10年组平均角膜厚度高于理论计算值,说明角膜基质值切削后有一定的增殖。结论:准分子激光原位角膜磨镶术治疗近视远期疗效稳定,手术安全性好。Objective： To evaluate the long-term outcomes and safety of laser in situ keratomilesis（LASIK） for myopia.Methods： 39 cases（77 eyes）,who underwent LASIK,were divided into two groups： myopia ≤-6.0 D and 〉-6.0 D.All patients were followed-up for 10 years after surgery.The main parameters for evaulation were predictability,stability,safety and efficacy.Uncorrected visual acuity（UCVA）,best-corrected visual acuity（BCVA）,refractions,topography,corneal thickness and postoperative complications were recorded at 10 years.Results： At the 10th year,63% of eyes with myopia ≤-6.0 D and 42% of eyes with myopia〉-6.0 D had 1.0 or better UCVA,27% of eyes with myopia ≤-6.0 D and 58% of eyes with myopia〉-6.0 D had less than 1.0 UCVA.98% of eyes with myopia ≤-6.0 D and 72% of eyes with myopia〉-6.0 D had 1.0 or better BCVA（P 〈 0.05）.There were significant differences at values of Diff value on anterior and posterior surface,Irreg at 3 mm and 5 mm zone obtained from Orbscan Ⅱand corneal thickness between pre-and post-operation（P 〈 0.01）.Mean corneal thickness at the 10th year postoperatively was higher than attempted residual corneal thickness after ablation,it suggested that the stroma of cornea proliferated.Conclusion：LASIK surgery is safe and has predictable and stable results in refractive and visual outcomes in correcting myopia on long-term follow-up.

关 键 词：近视 准分子激光原位角膜磨镶术 远期疗效 安全性 

分 类 号：R778.11[医药卫生—眼科]